{"id":211980,"date":"2026-02-10T11:06:00","date_gmt":"2026-02-10T16:06:00","guid":{"rendered":"https:\/\/news-you-need.com\/index.php\/2026\/02\/10\/astrazeneca-bets-on-continued-oncology-demand-for-2026-growth\/"},"modified":"2026-02-10T11:10:09","modified_gmt":"2026-02-10T16:10:09","slug":"astrazeneca-bets-on-continued-oncology-demand-for-2026-growth","status":"publish","type":"post","link":"https:\/\/news-you-need.com\/index.php\/2026\/02\/10\/astrazeneca-bets-on-continued-oncology-demand-for-2026-growth\/","title":{"rendered":"AstraZeneca bets on continued oncology demand for 2026 growth"},"content":{"rendered":"<p><a href=\"https:\/\/www.pharmaceutical-technology.com\/news\/astrazeneca-bets-on-continued-oncology-demand-for-2026-growth\/\">AstraZeneca bets on continued oncology demand for 2026 growth<\/a><\/p>\n<p><a href=\"https:\/\/www.pharmaceutical-technology.com\/news\/astrazeneca-bets-on-continued-oncology-demand-for-2026-growth\/\">https:\/\/www.pharmaceutical-technology.com\/news\/astrazeneca-bets-on-continued-oncology-demand-for-2026-growth\/<\/a><\/p>\n<p>Publish Date: <a href=\"publish_date]\">2026-02-10 11:06:00<\/a><\/p>\n<p>Source Domain: <a href=\"www.pharmaceutical-technology.com\">www.pharmaceutical-technology.com<\/a><\/p>\n<p>                                    AstraZeneca reported full year 2025 revenue of $58.7bn, up 8% at CER compared to 2024. Image credit: Michael Vi via Shutterstock.com. <\/p>\n<p class=\"drop-cap\">AstraZeneca expects profits to increase in 2026, as it counts on strong demand for its oncology portfolio continuing despite geopolitical pressures and patent expiry headwinds.<\/p>\n<p>AstraZeneca reported full year 2025 revenue of $58.7bn, up 8% at constant exchange rate (CER) compared to 2024. Oncology drug sales were a big driver for the drugmaker\u2019s growth, with revenue in the business increasing 14% to $25.6bn in 2025 compared to the year before.<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.pharmaceutical-technology.com\/wp-content\/themes\/goodlife-wp-B2B\/assets\/images\/GMS-logo.svg\" alt=\"\"\/><\/p>\n<h4> Discover B2B Marketing That Performs <\/h4>\n<p>\n\t\t\t\t\t\tCombine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.\n\t\t\t\t\t<\/p>\n<p>\n\t\t\t\t\t\t\tFind out more <span><\/span><\/p>\n<p>Lung cancer drug Tagrisso (osimertinib) was the top-selling product in the oncology segment, generating $7.25bn in sales for the year. Immunotherapy Imfinzi netted $6.06bn in 2025, boosted by US approvals in bladder cancer and gastric and gastroesophageal junction (GEJ) cancers. Sales for HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) saw a significant sales increase, surging 40% to reach $2.78bn in 2025.<\/p>\n<p>In an earnings call, Imfinzi and Enhertu were earmarked by AstraZeneca\u2019s senior leadership team as key revenue drivers for 2026, boosted by recent and upcoming cancer indication expansions. \u00a0<\/p>\n<p>Enhertu, co-marketed with Daiichi Sankyo, is forecast to generate global sales of $14.3bn in 2031, according to analysis by&#8230;<\/p>\n<p><a href=\"https:\/\/www.pharmaceutical-technology.com\/news\/astrazeneca-bets-on-continued-oncology-demand-for-2026-growth\/\">Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca bets on continued oncology demand for 2026 growth https:\/\/www.pharmaceutical-technology.com\/news\/astrazeneca-bets-on-continued-oncology-demand-for-2026-growth\/ Publish Date: 2026-02-10 11:06:00 Source&#8230;<\/p>\n","protected":false},"author":1,"featured_media":211981,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/www.pharmaceutical-technology.com\/wp-content\/uploads\/sites\/24\/2026\/02\/shutterstock_1832244673.jpg","fifu_image_alt":"","footnotes":""},"categories":[8],"tags":[],"class_list":["post-211980","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology"],"_links":{"self":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/211980"}],"collection":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/comments?post=211980"}],"version-history":[{"count":1,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/211980\/revisions"}],"predecessor-version":[{"id":211982,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/211980\/revisions\/211982"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/media\/211981"}],"wp:attachment":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/media?parent=211980"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/categories?post=211980"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/tags?post=211980"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}